Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 known ✓ | P31645 | 3/20 | 0.70 |
| ▸ | SLC6A2 known ✓ | P23975 | 2/20 | 0.70 |
| ▸ | SLC6A3 known ✓ | Q01959 | 2/20 | 0.70 |
| ▸ | ADRB2 known ✓ | P07550 | 1/20 | 0.50 |
| ▸ | ADRB1 known ✓ | P08588 | 1/20 | 0.50 |
| ▸ | ADRB3 known ✓ | P13945 | 1/20 | 0.50 |
| ▸ | ADRA1D known ✓ | P25100 | 1/20 | 0.50 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.50 |
| ▸ | ADRA1B known ✓ | P35368 | 1/20 | 0.50 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.70 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30448521 | 1.00 | TAAR1 (0.70) | TAAR1SLC6A4SLC6A2SLC6A3CYP2D6 | |
| Hydrochloric Acid SCHEMBL35210364 | 1.00 | TAAR1 (0.70) | TAAR1SLC6A4SLC6A2SLC6A3CYP2D6 | |
| Hydrochloric Acid SCHEMBL25314458 | 1.00 | TAAR1 (0.70) | TAAR1SLC6A4SLC6A2SLC6A3CYP2D6 | |
| SCHEMBL29350327 | 0.98 | TAAR1 (0.72) | TAAR1SLC6A4SLC6A2SLC6A3CYP2D6 | |
| SCHEMBL30503037 | 0.98 | TAAR1 (0.72) | TAAR1SLC6A4SLC6A2SLC6A3CYP2D6 | |
| SCHEMBL30434262 | 0.98 | TAAR1 (0.72) | TAAR1SLC6A4SLC6A2SLC6A3CYP2D6 | |
| SCHEMBL715096 | 0.98 | TAAR1 (0.72) | TAAR1SLC6A4SLC6A2SLC6A3CYP2D6 | |
| SCHEMBL25188324 | 0.98 | TAAR1 (0.72) | TAAR1SLC6A4SLC6A2SLC6A3CYP2D6 | |
| SCHEMBL896903 | 0.98 | TAAR1 (0.72) | TAAR1SLC6A4SLC6A2SLC6A3CYP2D6 | |
| Hydrochloric Acid SCHEMBL25193660 | 0.88 | SLC6A4 (0.55) | TAAR1SLC6A4SLC6A2SLC6A3CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12577222-B2 | Phenethylamine compounds salts, polymorphic forms and methods of use thereof | TERRAN BIOSCIENCES INC. (US) | 2026-03-17 | — | — | US | disclosed |
| US-20240409526-A1 | PHENETHYLAMINE COMPOUNDS SALTS, POLYMORPHIC FORMS AND METHODS OF USE THEREOF | TERRAN BIOSCIENCES INC (US) | 2024-12-12 | — | — | US | disclosed |
| US-20240327371-A1 | PHENETHYLAMINE COMPOUNDS SALTS, POLYMORPHIC FORMS AND METHODS OF USE THEREOF | TERRAN BIOSCIENCES INC. (US) | 2024-10-03 | — | — | US | disclosed |
| EP-4433466-A2 | PHENETHYLAMINE COMPOUNDS SALTS, POLYMORPHIC FORMS AND METHODS OF USE THEREOF | Terran Biosciences Inc. (US) | 2024-09-25 | — | — | EP | disclosed |
| US-11958821-B2 | Phenethylamine compounds salts, polymorphic forms and methods of use thereof | TERRAN BIOSCIENCES INC. (US) | 2024-04-16 | — | — | US | disclosed |
| US-20230227422-A1 | PHENETHYLAMINE COMPOUNDS SALTS, POLYMORPHIC FORMS AND METHODS OF USE THEREOF | TERRAN BIOSCIENCES INC. | 2023-07-20 | — | — | US | disclosed |
| WO-2023137446-A1 | PRODRUGS OF 3,4-METHYLENEDIOXY- N-ETHYL-AMPHETAMINE (MDEA) AND USES THEREOF | TERRAN BIOSCIENCES INC. (US) | 2023-07-20 | — | — | WO | disclosed |
| US-20230202998-A1 | PHENETHYLAMINE COMPOUNDS SALTS, POLYMORPHIC FORMS AND METHODS OF USE THEREOF | TERRAN BIOSCIENCES INC (US) | 2023-06-29 | — | — | US | disclosed |
| WO-2023092044-A2 | PHENETHYLAMINE COMPOUNDS SALTS, POLYMORPHIC FORMS AND METHODS OF USE THEREOF | TERRAN BIOSCIENCES, INC. (US) | 2023-05-25 | — | — | WO | disclosed |
| EP-2875362-A1 | TEST KIT FOR THE QUANTITATIVE DETERMINATION OF NARCOTIC DRUGS | Chiron AS (NO) | 2015-05-27 | — | — | EP | disclosed |
| US-20150025063-A1 | Antiparkinsonian Action of Phenylisopropylamines | UNIV DUKE (US) | 2015-01-22 | — | — | US | disclosed |
| US-8877802-B2 | Antiparkinsonian action of phenylisopropylamines | Duke Univerity (US) | 2014-11-04 | — | — | US | disclosed |
| WO-2014013063-A1 | TEST KIT FOR THE QUANTITATIVE DETERMINATION OF NARCOTIC DRUGS | CHIRON AS (NO) | 2014-01-23 | — | — | WO | disclosed |
| EP-2687854-A1 | Test kit for the quantitative determination of narcotic drugs | Chiron AS (NO) | 2014-01-22 | — | — | EP | disclosed |
| WO-2007016190-A2 | ANTIPARKINSONIAN ACTION OF PHENYLISOPROPYLAMINES | DUKE UNIVERSITY (US) | 2007-02-08 | — | — | WO | disclosed |
| US-20070027208-A1 | Antiparkinsonian Action of Phenylisopropylamines | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12577222-B2 | Phenethylamine compounds salts, polymorphic forms and methods of use thereof | DRD2, DRD1, DRD3 | SLC6A4 59/4885SLC6A2 17/4885SLC6A3 5/4885 |
| US-20240409526-A1 | PHENETHYLAMINE COMPOUNDS SALTS, POLYMORPHIC FORMS AND METHODS OF USE THEREOF | DRD2, DRD3, DRD1 | SLC6A4 16/4885SLC6A2 11/4885SLC6A3 4/4885 |
| US-20070027208-A1 | Antiparkinsonian Action of Phenylisopropylamines | PNMT, SNCA, COMT | SLC6A4 178/4885SLC6A2 97/4885SLC6A3 36/4885 |
| US-20150025063-A1 | Antiparkinsonian Action of Phenylisopropylamines | PNMT, SNCA, COMT | SLC6A4 178/4885SLC6A2 97/4885SLC6A3 36/4885 |
| US-20240327371-A1 | PHENETHYLAMINE COMPOUNDS SALTS, POLYMORPHIC FORMS AND METHODS OF USE THEREOF | DRD2, DRD3, DRD1 | SLC6A4 16/4885SLC6A2 11/4885SLC6A3 4/4885 |
| US-20230227422-A1 | PHENETHYLAMINE COMPOUNDS SALTS, POLYMORPHIC FORMS AND METHODS OF USE THEREOF | DRD2, DRD3, DRD1 | SLC6A4 16/4885SLC6A2 11/4885SLC6A3 4/4885 |
| US-20230202998-A1 | PHENETHYLAMINE COMPOUNDS SALTS, POLYMORPHIC FORMS AND METHODS OF USE THEREOF | DRD2, DRD3, DRD1 | SLC6A4 16/4885SLC6A2 11/4885SLC6A3 4/4885 |
| US-11958821-B2 | Phenethylamine compounds salts, polymorphic forms and methods of use thereof | DRD2, DRD3, DRD1 | SLC6A4 16/4885SLC6A2 11/4885SLC6A3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.